IL179730A0 - Novel cis-imidazolines - Google Patents

Novel cis-imidazolines

Info

Publication number
IL179730A0
IL179730A0 IL179730A IL17973006A IL179730A0 IL 179730 A0 IL179730 A0 IL 179730A0 IL 179730 A IL179730 A IL 179730A IL 17973006 A IL17973006 A IL 17973006A IL 179730 A0 IL179730 A0 IL 179730A0
Authority
IL
Israel
Prior art keywords
imidazolines
novel cis
cis
novel
Prior art date
Application number
IL179730A
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34969621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL179730(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL179730A0 publication Critical patent/IL179730A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
IL179730A 2004-06-17 2006-11-30 Novel cis-imidazolines IL179730A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58044104P 2004-06-17 2004-06-17
US67419605P 2005-04-22 2005-04-22
PCT/EP2005/006167 WO2005123691A1 (en) 2004-06-17 2005-06-08 Novel cis-imidazolines

Publications (1)

Publication Number Publication Date
IL179730A0 true IL179730A0 (en) 2007-05-15

Family

ID=34969621

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179730A IL179730A0 (en) 2004-06-17 2006-11-30 Novel cis-imidazolines

Country Status (16)

Country Link
US (1) US7893278B2 (en)
EP (1) EP1758868A1 (en)
JP (1) JP4809336B2 (en)
KR (1) KR100855929B1 (en)
AR (1) AR049647A1 (en)
AU (1) AU2005254643A1 (en)
BR (1) BRPI0512237A (en)
CA (1) CA2569598A1 (en)
IL (1) IL179730A0 (en)
MX (1) MXPA06014806A (en)
NO (1) NO20070295L (en)
NZ (1) NZ551659A (en)
RU (1) RU2408593C2 (en)
SG (1) SG148177A1 (en)
TW (1) TW200637828A (en)
WO (1) WO2005123691A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006224765B2 (en) 2005-03-16 2012-02-09 F.Hoffmann-La Roche Ag CIS-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
EP2130822A1 (en) 2005-12-01 2009-12-09 F. Hoffmann-La Roche AG 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
EP1979338A1 (en) * 2006-01-18 2008-10-15 F.Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
CN101605798A (en) 2006-12-14 2009-12-16 第一三共株式会社 Imidazothiazole derivative
PT2118123E (en) * 2007-01-31 2016-02-10 Harvard College Stabilized p53 peptides and uses thereof
ES2430067T3 (en) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Sewn polypeptides
US7625895B2 (en) * 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008144614A1 (en) * 2007-05-21 2008-11-27 Lubrizol Advanced Materials, Inc. Polyurethane polymer
EP2249832A4 (en) * 2008-01-30 2011-12-21 Agency Science Tech & Res Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
EP2271338A4 (en) * 2008-03-31 2011-05-04 Agency Science Tech & Res Method for treating neurological disorders with imidazolium and imidazolinium compounds
EP2298778A4 (en) 2008-06-12 2011-10-05 Daiichi Sankyo Co Ltd Imidazothiazole derivative having 4,7-diazaspiroý2.5¨octane ring structure
ES2463820T3 (en) 2009-01-16 2014-05-29 Daiichi Sankyo Company, Limited Imidazothiazole derivative that has a proline ring structure
JO2998B1 (en) 2010-06-04 2016-09-05 Amgen Inc Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
US8889863B2 (en) 2010-07-16 2014-11-18 Vanderbilt University Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds
KR20180058866A (en) 2010-08-13 2018-06-01 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles
EP2621275B1 (en) 2010-09-30 2018-03-28 St. Jude Children's Research Hospital Aryl-substituted imidazoles
MX352672B (en) 2011-09-27 2017-12-04 Amgen Inc Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer.
BR112014009418A2 (en) 2011-10-18 2017-04-18 Aileron Therapeutics Inc peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6526563B2 (en) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド Disubstituted amino acids and methods for their preparation and use
BR112015013611A2 (en) 2012-12-20 2017-11-14 Merck Sharp & Dohme compound and pharmaceutical composition
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
ES2875853T3 (en) 2013-03-15 2021-11-11 Univ Texas Method of treating fibrosis
JOP20200296A1 (en) 2013-06-10 2017-06-16 Amgen Inc Processes of Making and Crystalline Forms of a MDM2 Inhibitor
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
JP6688224B2 (en) 2014-01-28 2020-04-28 バック インスティテュート フォー リサーチ オン エイジング Treatment of osteoarthritis in joints by administration of means that inhibit MDM2
JP2017533889A (en) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycles and uses thereof
CN107106642B (en) 2014-09-24 2021-02-26 艾瑞朗医疗公司 Peptidomimetic macrocycles and formulations thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (en) 2015-09-10 2018-08-03 艾瑞朗医疗公司 Peptidomimetic macrocyclic compound as MCL-1 conditioning agents
EP3429570A1 (en) 2016-03-15 2019-01-23 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EP3429571A1 (en) 2016-03-15 2019-01-23 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PL3458101T3 (en) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Protac antibody conjugates and methods of use
CA3033850C (en) 2017-06-16 2020-02-11 Unity Biotechnology, Inc. Synthesis method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
JP7204391B2 (en) * 2018-09-18 2023-01-16 株式会社東芝 Acid gas absorbent, method for removing acid gas, and apparatus for removing acid gas
KR102622992B1 (en) * 2021-03-29 2024-01-10 주식회사 퓨전바이오텍 Method for preparing imidazoline derivatives and intermediates thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2441498A (en) * 1943-07-15 1948-05-11 Astra Apotekarnes Kem Fab Alkyl glycinanilides
JPH02101065A (en) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd Imidazoline derivative
DE4203547A1 (en) 1992-02-07 1993-08-12 Knoll Ag METHOD FOR RACEMAT SEPARATION OF VERAPAMIL
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
US6653501B2 (en) 2001-06-27 2003-11-25 Napro Biotherapeutics, Inc. Chiral resolution method for producing compounds useful in the synthesis of taxanes
ATE389400T1 (en) * 2001-12-18 2008-04-15 Hoffmann La Roche CIS-2,4,5-TRIPHENYL-IMIDAZOLINE AND THEIR USE IN THE TREATMENT OF TUMORS
JP4361798B2 (en) * 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Cis-imidazoline as an MDM2 inhibitor
ES2314660T3 (en) * 2004-05-18 2009-03-16 F. Hoffmann-La Roche Ag NEW CIS-IMIDAZOLINAS.

Also Published As

Publication number Publication date
KR20070027590A (en) 2007-03-09
JP2008502620A (en) 2008-01-31
US20050282803A1 (en) 2005-12-22
RU2408593C2 (en) 2011-01-10
EP1758868A1 (en) 2007-03-07
AU2005254643A1 (en) 2005-12-29
US7893278B2 (en) 2011-02-22
KR100855929B1 (en) 2008-09-02
NZ551659A (en) 2010-08-27
CA2569598A1 (en) 2005-12-29
AR049647A1 (en) 2006-08-23
BRPI0512237A (en) 2008-02-19
SG148177A1 (en) 2008-12-31
RU2007101275A (en) 2008-07-27
WO2005123691A1 (en) 2005-12-29
MXPA06014806A (en) 2007-02-12
NO20070295L (en) 2007-01-17
TW200637828A (en) 2006-11-01
JP4809336B2 (en) 2011-11-09

Similar Documents

Publication Publication Date Title
ZA200609595B (en) Novel CIS-Imidazolines
IL179730A0 (en) Novel cis-imidazolines
TWI372750B (en) Novel hydroxy-6-heteroarylphenanthridines
GB0415789D0 (en) Novel combination
GB0427131D0 (en) Novel combination
ZA200610303B (en) Novel cis-imidazolines
GB0414026D0 (en) Novel uses
ZA200606635B (en) Novel isoamido-substituted hydroxy-6-phenylphenanthridines
GB0408865D0 (en) Novel benzoxazocines
ZA200608482B (en) Novel tetrahydropyridothiophenes
GB0505847D0 (en) Novel benzoxazocines
GB0408863D0 (en) Novel benzoxazocines
GB0408862D0 (en) Novel benzoxazocines
GB0422681D0 (en) Novel uses
GB0422671D0 (en) Novel uses
GB0420316D0 (en) Novel uses
GB0423752D0 (en) Novel uses
GB0423751D0 (en) Novel uses
GB0423750D0 (en) Novel uses
GB0420274D0 (en) Novel uses
GB0422684D0 (en) Novel uses
GB0422683D0 (en) Novel uses
GB0420289D0 (en) Novel uses
GB0422680D0 (en) Novel uses
GB0422679D0 (en) Novel uses